RxDoctor Payments Data

Thomas Hildner, MD

Family Medicine · Bozeman, MTNPI 1174608210

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.7% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations.

$748in general payments, 2019–2025

Across 40 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$130
  • Astellas Pharma US Inc$74
  • Inspire Medical Systems, Inc.$74
  • Amgen$65
  • Lilly USA, LLC$64
  • Exact Sciences$62
  • plus $280 from 9 others

What the payments were for

  • Food & beverage$71696%
  • Education$324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$748 in reported general payments places this provider in the 85th percentile of 426 family medicine providers in Montana.

See all family medicine providers in Montana

Medicare billing

Part B allowed, 2024
$50,969
Medicare patients
440
Services billed
838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$68,828
XareltoRivaroxaban19$27,757
OzempicSemaglutide27$26,010
JardianceEmpagliflozin15$22,063
MounjaroTirzepatide11$11,171
Fluticasone-SalmeterolFluticasone Propion/Salmeterol67$10,354
Breo ElliptaFluticasone/Vilanterol14$9,910
Levothyroxine Sodium480$5,856
Atorvastatin Calcium496$5,706
Gabapentin260$3,615
Methylphenidate Hcl19$3,357
Amlodipine Besylate376$2,922
Losartan Potassium223$2,582
Lisinopril355$2,375
Albuterol Sulfate HfaAlbuterol Sulfate66$2,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$68,82871 claims
Novo NordiskOzempic$47$26,01027 claims
Lilly USA, LLCMounjaro$64$11,17111 claims
GSKBreo Ellipta$29$9,91014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 426 family medicine providers in Montana.

Other family medicine in Bozeman

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →